Premium
readers over at PropThink.com are already up 15% since our buy recommendation
was issued on Amicus Therapeutics [FOLD] on August 7 at $4.00
per share.
Though
the investment premise remains intact, investors might want to either lock in
existing short-term gains, or buy September 5 calls as downside insurance
against any near-term clinical surprises.
Investment Thesis
Albeit
the investment thesis is focused on monotherapy use of its proprietary, pharmacological
chaperone migalastat in Fabry Disease, there are value-creating assets
that should become more visible in late 2015. In the treatment of Pompe disease
(a glycogen storage disorder caused by deficiency of an enzyme called acid
α-glucosidase), Amicus is looking to leverage its proprietary Chaperone-Advanced
Replacement Therapy platform to improve currently
marketed ERTs through co-administration of a pharmacological chaperone prior to
ERT infusion, and/ or to develop next-generation ERTs that consist of a
proprietary lysosomal enzyme therapy co-formulated with a pharmacological
chaperone.
Those
investors looking for additional insight into our thoughts on FOLD and visible
catalysts, such as Study 012, might consider opening their wallets and
purchasing a subscription to PropThink.com.
Editor David J Phillips no longer holds a financial
interest in any stocks mentioned in this article. The 10Q Detective has a Full
Disclosure Policy.
No comments:
Post a Comment